The KRAS
Acetonitriles
/ antagonists & inhibitors
Animals
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Proliferation
Disease Models, Animal
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Mice
Piperazines
/ antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)
/ antagonists & inhibitors
Pyrimidines
/ antagonists & inhibitors
Tumor Microenvironment
/ drug effects
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
04
06
2020
revised:
03
12
2020
accepted:
08
03
2021
pubmed:
17
3
2021
medline:
27
1
2022
entrez:
16
3
2021
Statut:
ppublish
Résumé
KRAS
Identifiants
pubmed: 33722854
pii: 1535-7163.MCT-20-0462
doi: 10.1158/1535-7163.MCT-20-0462
pmc: PMC8444277
mid: NIHMS1736423
doi:
Substances chimiques
Acetonitriles
0
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Piperazines
0
Pyrimidines
0
adagrasib
8EOO6HQF8Y
Hras protein, mouse
EC 3.6.5.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-985Subventions
Organisme : NCI NIH HHS
ID : R01 CA166480
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Oncotarget. 2015 Oct 20;6(32):32368-79
pubmed: 26468985
Cancer Cell. 2019 Apr 15;35(4):559-572.e7
pubmed: 30905761
Lab Invest. 2017 Feb;97(2):166-175
pubmed: 27991907
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Exp Med. 2006 Jul 10;203(7):1651-6
pubmed: 16801397
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
Clin Cancer Res. 2019 May 1;25(9):2691-2698
pubmed: 30642913
J Thorac Oncol. 2019 Jun;14(6):1095-1101
pubmed: 30738221
Cancer Res. 2013 Jan 15;73(2):539-49
pubmed: 23108136
BMC Genomics. 2014 Mar 13;15:190
pubmed: 24621249
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609-14
pubmed: 9520413
Oncoimmunology. 2016 Mar 16;5(5):e1131379
pubmed: 27467949
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
Mol Immunol. 2014 Apr;58(2):160-8
pubmed: 24365750
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Mol Interv. 2008 Feb;8(1):22-7
pubmed: 18332481
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
Cancer Res. 1995 Oct 15;55(20):4575-80
pubmed: 7553632
Front Oncol. 2014 Apr 02;4:70
pubmed: 24765614
EMBO Mol Med. 2017 May;9(5):672-686
pubmed: 28341702
Br J Cancer. 2019 Jan;120(1):57-62
pubmed: 30377342
Cancer Med. 2015 Jun;4(6):897-902
pubmed: 25773971
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
Int J Cancer. 2012 Apr 15;130(8):1733-44
pubmed: 21544811
Cancer Res. 2000 Jan 15;60(2):490-8
pubmed: 10667605
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074